Skip to main content
Zai Lab Limited logo

Zai Lab Limited — Investor Relations & Filings

Ticker · 9688 ISIN · KYG9887T1168 LEI · 549300P2UYQ9U5LY1T58 HKEX Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2025-06-19 Declaration of Voting R…
Country KY Cayman Islands
Listing HKEX 9688

About Zai Lab Limited

http://www.zailaboratory.com

Zai Lab Limited is an innovative, research-based, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing transformative therapies that address medical conditions with significant unmet needs. The company focuses its pipeline and development efforts across four core therapeutic areas: oncology, immunology, neuroscience, and infectious disease. Zai Lab employs a strategy of internal research and global partnerships to advance best-in-class and first-in-class medicines. A key commercial product is ZEJULA (niraparib), utilized as a maintenance treatment for ovarian cancer in markets including mainland China.

Recent filings

Filing Released Lang Actions
VOTING RESULTS OF ANNUAL GENERAL MEETING
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement titled “VOTING RESULTS OF ANNUAL GENERAL MEETING,” detailing the vote counts (for, against, abstentions) on each resolution at the 2025 annual general meeting. It does not contain financial statements, management discussion, or proxy solicitation materials beyond referencing the Proxy Statement, nor is it the full annual report. It specifically reports shareholder voting outcomes, fitting the definition of a Declaration of Voting Results & Voting Rights Announcements (Code: DVA).
2025-06-19 English
GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS
Share Issue/Capital Change Classification · 85% confidence The document is an announcement under the HK Listing Rules of the grant of share options and restricted share units under the company’s 2024 Equity Incentive Plan. It details the number of ADSs, vesting schedules, exercise prices and plan terms. This is a capital change involving issuance of option and RSU awards (i.e., a new share-based issue), and not an earnings release, management change, or report publication announcement. Therefore it fits the “Share Issue/Capital Change” category.
2025-06-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2025
Regulatory Filings Classification · 85% confidence The document is an HKEX statutory monthly return (Form FF301) under Listing Rule 19B detailing movements in share capital, issued shares, treasury shares, option exercises and other share arrangements for May 2025. It is not an earnings release, AGM material, board change, M&A or dividend notice, but a regulatory return mandated by the Stock Exchange describing share capital movements. This does not itself constitute a standalone capital change announcement (no net share issue), but is a standard listing rule compliance filing. Therefore it falls under the general "Regulatory Filings" category (RNS).
2025-06-05 English
GRANT OF RESTRICTED SHARE UNITS
Share Issue/Capital Change Classification · 85% confidence The document is a Hong Kong Listing Rules announcement detailing the grant of restricted share units under the company’s 2024 Equity Incentive Plan. It is not an earnings release, management change, or regulatory notice of a published report, but rather an equity issuance under the existing share plan. This aligns with a Share Issue/Capital Change announcement.
2025-05-14 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2025
Share Issue/Capital Change Classification · 90% confidence The document is an HKEX monthly return (FF301) detailing movements in authorised/issued share capital, exercises of share options, RSUs/PSUs vesting and other share issuance activities for the month. It is a regulatory disclosure focused on new share issues and capital changes rather than a full report, earnings release or management commentary. This aligns with the “Share Issue/Capital Change” category (SHA).
2025-05-08 English
OVERSEAS REGULATORY ANNOUNCEMENT - FORM 10-Q
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-Q, which is the standard U.S. Securities and Exchange Commission (SEC) filing for a quarterly report. It contains comprehensive financial statements, management's discussion and analysis (MD&A), and other required disclosures for the period ended March 31, 2025. Although it includes a brief cover letter for a Hong Kong regulatory announcement, the bulk of the document is the actual 10-Q report itself, which qualifies as an Interim/Quarterly Report (IR). Q1 2025
2025-05-08 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.